Global Burden of Chronic Lymphocytic Leukemia Up From 1990 to 2019
The global burden of CLL increased from 40,537 cases in 1990 to 103,467 in 2019.
Lymphoma News
LYMPHOMA ADVISOR
Lymphoma News
Zydelig US Indications Withdrawn for Follicular Lymphoma, Small Lymphocytic Leukemia
Continued approval required further verification and description of clinical benefit in confirmatory trials.
PET-Guided Treatment May Reduce Toxicity Without Compromising Efficacy in Advanced Hodgkin Lymphoma
Survival outcomes were similar with the PET-driven approach and standard care.
T-Cell Responses to COVID-19 Vaccines May Benefit Anti-CD20-Treated Lymphoma Patients
Despite an inferior rate of seroconversion, lymphoma patients treated with anti-CD20 therapy did mount T-cell responses.
Tisagenlecleucel Deemed Effective in Relapsed/Refractory Follicular Lymphoma
The overall response rate was 86.2%, and the complete response rate was 69.1%.
Younger Patients Who Survive Non-Hodgkin Lymphoma Face Higher Risk of Comorbidities
Researchers sought to determine the risk of comorbidities in younger patients who survive NHL compared with older patients.
Platelet, Hemoglobin Levels Related to COVID-19 Mortality in Hematologic Malignancies
A study suggests low platelet or low hemoglobin levels may be factors linked to COVID-19 mortality in patients with hematologic malignancies.
ASCO Releases Guideline for Managing Immune-Related Adverse Events of CAR-T Therapy
The guideline focuses on the treatment of CRS and ICANS in patients undergoing CAR-T therapy for hematologic cancers.
First-Line Axi-Cel Appears Effective in High-Risk Large B-Cell Lymphoma
At a median follow-up of 15.9 months, the median duration of response was not reached.
Smartphone App Helps Guide Use of CAR T-Cell, BiTE Therapy
The “myTcell” app is expected to be released in the United States in 2022.
Anakinra Can Prevent Severe CRS, ICANS After CAR T-Cell Therapy
There was 1 case of grade 3 CRS and 1 case of grade 4 CRS.
Novel Agents Lead to Changes in Therapeutic Strategies and Sequencing for CLL
Data were analyzed from patients diagnosed with CLL between 2000 and 2020 from 77 institutions affiliated with the ERIC.
Acalabrutinib Effective for Relapsed/Refractory CLL at 3 Years
The findings support the use of acalabrutinib in patients with relapsed/refractory CLL, including those with high-risk features.
Black Patients Less Likely to Receive Novel Agents as First-Line CLL Therapy
Investigators revealed unequal access to novel agents when comparing Black and White patients with CLL.
Lymphadenopathy in CLL Patients Predicts Richter’s Syndrome Risk After Ibrutinib
The retrospective study included 559 patients who had received ibrutinib for CLL, of whom 179 progressed according to iwCLL criteria.
Ibrutinib Plus Venetoclax Produces Superior uMRD Responses in CLL
Researchers presented updated findings from the GLOW trial.
Tocilizumab Shortage Prompts Temporary REMS Change for CAR T-Cell Therapy
The FDA has issued a temporary policy for when it may not be feasible to have 2 doses of tocilizumab on-site.
Hospitalization, ED Visits Highest in First Month After CAR T-Cell Infusion
Sixty-seven percent of rehospitalizations occurred within the first month of CAR T-cell infusion.
No EFS Benefit With Second-Line Tisa-Cel in Relapsed/Refractory Non-Hodgkin Lymphoma
The median event-free survival was 3 months in both treatment arms.
Third COVID-19 Vaccine Dose Boosts Seroconversion Rate in CLL Patients
Vaccine responses were evaluated after dose 1 for 158 CLL patients, after dose 2 for 506 patients, and after dose 3 for 66 patients.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
Loading... 
Loading...